Herbal Drug Interactions

Introduction & why herbal interactions matter

• Definition — a herbal drug interaction is a subset of drug–drug interaction in which a herbal/botanical product or dietary supplement modifies the response to a conventional drug — usually quantitative (effect increased or decreased), occasionally qualitative (a new abnormal response).
• Regulation drives the risk — in the USA, dietary supplements (incl. herbal "medications") are regulated as foods under the DSHEA 1994 — marketed with no pre-marketing proof of efficacy or safety; the FDA must prove a product harmful before restricting it. India's parallel regulator (DCGI) likewise can withdraw an unsafe supplement but does not pre-clear it.
• Scale of use — WHO estimates ~80% of developing-country populations use plant medicines; US supplement sales exceeded $32 billion (2021); ~18% of US adults used non-vitamin/mineral supplements (2012 NHIS).
• Four structural reasons herbal interactions are dangerous & under-recognised — (1) unstandardised, variable constituents — a botanical may contain hundreds of constituents varying with species, plant part and extraction, mostly not standardised; (2) misidentification, adulteration & contamination — DNA-barcoding found substitution in 32% of products (Newmaster 2013); adulterants include steroids, PDE-5 inhibitors, heavy metals and aflatoxin; (3) under-reporting of adverse events; (4) patients do not disclose — "natural" is assumed safe, so a non-judgemental history is essential.
• "Natural ≠ safe" — botanicals may be inert or toxic — misidentified mushrooms cause liver failure, contaminated tryptophan caused eosinophilia–myalgia syndrome, and Aristolochia causes nephropathy and urothelial cancer. Concentrated extracts carry far more interaction risk than dietary amounts (food/herbal teas).
• Where the danger concentrates — interactions matter most with narrow-therapeutic-index (NTI) object drugs — anticoagulants, antiseizure drugs, antiretrovirals, immunosuppressants (calcineurin inhibitors), digoxin and cancer chemotherapeutics — where a small exposure change crosses the efficacy/toxicity threshold.